Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial

Michal Geva; Y Paul Goldberg; Melanie L. Leitner; Kelly Chen; Wei Feng; Noga Gershoni Emek; James D. Berry; Sabrina Paganoni; Jeremy Shefner; Merit ECudkowicz; Michael R. Hayden

doi:10.1016/j.neurot.2025.e00675

Back

Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial

Journal article

Peer reviewed

Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial

Michal Geva, Y Paul Goldberg, Melanie L. Leitner, Kelly Chen, Wei Feng, Noga Gershoni Emek, James D. Berry, Sabrina Paganoni, Jeremy Shefner, Merit ECudkowicz, …

Neurotherapeutics, Vol.22(4), pp.e00675-e00675

07/2025

DOI: https://doi.org/10.1016/j.neurot.2025.e00675

Files and links (1)

url

https://doi.org/10.1016/j.neurot.2025.e00675View

Published (Version of record) Open

Metrics

1 Record Views

Details

Title: Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial
Creators: Michal Geva - Agile Therapeutics (United States)
Y Paul Goldberg - Agile Therapeutics (United States)
Melanie L. Leitner - BioVentures (United States)
Kelly Chen - Agile Therapeutics (United States)
Wei Feng - Agile Therapeutics (United States)
Noga Gershoni Emek - Agile Therapeutics (United States)
James D. Berry - Massachusetts General Hospital
Sabrina Paganoni - Massachusetts General Hospital
Jeremy Shefner - Barrow Neurological Institute
Merit ECudkowicz - Massachusetts General Hospital
Michael R. Hayden - Agile Therapeutics (United States)
Publication Details: Neurotherapeutics, Vol.22(4), pp.e00675-e00675
Publisher: Elsevier Inc
Identifiers: 991006262221902656
Academic Unit: Neurology
Language: English
Resource Type: Journal article